Treatment Clinical Trials for Chronic Lymphocytic Leukemia

Clinical trials are research studies that involve people. The clinical trials on this list are for chronic lymphocytic leukemia treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 161

  • Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

    The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and / or recommended dose (RD).
    Location: 5 locations

  • The Combination of Venetoclax and Obinutuzumab in Patients with Chronic Lymphocytic Leukemia (CLL)

    This phase II trial studies the effect of venetoclax and obinutuzumab in treating patients with chronic lymphocytic leukemia who have not received a previous treatment. Venetoclax blocks Bcl-2, a protein in cancer cells that helps those cells survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and / or make them more vulnerable to the effects of other treatments. Obinutuzumab targets a protein called CD20, which is found on the surface of B cells, the white blood cells that are affected by CLL. When obinutuzumab attaches to CD20, it both destroys the B cells and makes them more visible to the immune system. The immune system then attacks and destroys the cancerous B cells. Combining venetoclax and obinutuzumab has provided an alternative to chemotherapy for people with CLL. Researchers have found that combining venetoclax and obinutuzumab increases the drugs’ ability to fight cancer cells, and the drugs in combination may be more effective than the drugs on their own.
    Location: 5 locations

  • APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R / R Non-Hodgkin Lymphomas (NHL)

    Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either ibrutinib or venetoclax + rituximab therapy in subjects with TP53-mutant NHL, including relapsed and / or refractory (R / R) CLL and R / R MCL.
    Location: 5 locations

  • APG-2575 Study of Safety, Tolerability ,PK / PD in Patients With Hematologic Malignancies

    This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
    Location: 5 locations

  • FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

    This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed / refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
    Location: 4 locations

  • Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL / SLL

    Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.
    Location: 4 locations

  • Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

    An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
    Location: 4 locations

  • Venetoclax, Rituximab, and Combination Chemotherapy in Treating Patients with Richter Syndrome

    This phase II trial studies how well venetoclax, rituximab, and combination chemotherapy works in treating patients with Richter syndrome. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax, rituximab, and combination chemotherapy may work better in treating patients with Richter syndrome.
    Location: 4 locations

  • T-Lymphocytes in Treating Patients with Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and the best dose of laboratory-treated T lymphocytes in treating patients with Hodgkin lymphoma or non-Hodgkin lymphoma that is active or has returned after a period of improvement. Giving an infusion of a person's T lymphocytes that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells.
    Location: 4 locations

  • Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma

    This phase I trial studies the side effects of laboratory-treated T cells in treating patients with B-cell chronic lymphocytic leukemia, B-cell lymphoma, or multiple myeloma that has come back or has not gone away after treatment. This study combines two different ways of fighting disease, antibodies (proteins that protect the body from bacterial and other diseases) and T cells (special infection-fighting blood cells that can kill other cells, including cancer cells). Treating the T cells in the laboratory by adding an antibody may help the T cells last longer in the body and kill more cancer cells.
    Location: 4 locations

  • A Study Of The Selective PKC-β Inhibitor MS- 553

    A Phase I Dose-Escalation Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
    Location: 4 locations

  • Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

    Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in subjects with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.
    Location: 3 locations

  • Pembrolizumab and Umbralisib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

    This phase I trial studies side effects and best dose of pembrolizumab and umbralisib in treating patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma that have come back (relapsed) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and umbralisib may work better in treating patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.
    Location: 3 locations

  • CD19.CAR T Cells in Treating Participants with CD19 Positive Malignancies after Stem Cell Transplant

    This phase I trial studies the side effects and best dose of CD19.CAR T cells in treating participants with CD19 positive malignancies after stem cell transplant. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. T lymphocytes, such as CD19.CAR T cells, may kill tumor cells but there normally are not enough of them to kill all the tumor cells.
    Location: 3 locations

  • Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma

    This phase I trial studies the side effects and the best dose of genetically modified T-cells in treating patients with advanced non-Hodgkin's lymphoma. Biological therapies, such as genetically modified T-cells may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
    Location: 3 locations

  • Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

    This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells in all clinical trials including NCT04450069, A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies.
    Location: 4 locations

  • CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

    CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.
    Location: 4 locations

  • Intermittent Duvelisib Dosing in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
    Location: 3 locations

  • A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed / refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Location: 5 locations

  • ANCHOR Cells for the Treatment of Patients with Relapsed or Refractory CD19-Positive B-Cell Lymphoma or Leukemia, ANCHOR Study

    This phase I clinical trial studies the best dose and side effects of allogeneic natural killer T-cells expressing CD19-specific chimeric antigen receptor and interleukin-15 (ANCHOR cells) in treating patients with CD19-positive lymphoma or leukemia that have come back (relapsed) or do not respond to treatment (refractory). This trial combines two different ways of fighting disease, antibodies, and immune cells. Antibodies are types of proteins that protect the body from bacterial and other diseases. Immune cells, also called lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and lymphocytes have been used to treat patients with cancer. The antibody used in this study is called anti-CD19. It sticks to leukemia cells because of a substance on the outside of these cells called CD19. For this clinical trial, the anti-CD19 antibody has been changed so that instead of floating free in the blood it is now joined to the NKT cells, a special type of lymphocytes that can kill tumor cells but not very effectively on their own. When an antibody is joined to a T cell in this way, it is called a chimeric receptor. In the laboratory, it has also been found that NKT cells work better if proteins that stimulate lymphocytes are added, such as one called CD28. Adding the CD28 makes the cells last for a longer time in the body but may be not long enough for them to be able to kill the leukemia cells. Adding an extra stimulating protein, called IL-15, may allow the cells an even better chance of killing the leukemia cells. This trial evaluates whether putting the anti-CD19 chimeric receptor with CD28 and the IL-15 into NKT cells grown from a healthy individual may be more effective in treating patients with relapsed or refractory CD19-positive lymphoma or leukemia.
    Location: 3 locations

  • Acalabrutinib with or without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 3 locations

  • Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency

    This clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.
    Location: 3 locations

  • Accelerated Dose Venetoclax Ramp-Up for the Treatment of Newly Diagnosed, Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, SAVE Study

    This phase Ib trial studies the side effects of an accelerated dose ramp-up of venetoclax in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that is newly diagnosed, has come back (relapsed) or does not respond to treatment (refractory). Venetoclax is an oral drug inhibitor of BCL-2, a protein that regulates the death of cells in your body. Venetoclax is typically started at a low dose and increased on a weekly basis until the desired dose is reached. Giving an increased dose of venetoclax over a shorter period of time may be safe in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 2 locations

  • Copanlisib and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

    This phase II trial studies the effect of copanlisib given in combination with ibrutinib in treating patients with chronic lymphocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Copanlisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving copanlisib together with ibrutinib may kill more cancer cells.
    Location: 2 locations

  • A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

    CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
    Location: 2 locations